Ohr Pharmaceutical (OHRP) Reports Q1 Results; Pauses Enrollment in First Phase 3 Trial of Squalamine
Go back to Ohr Pharmaceutical (OHRP) Reports Q1 Results; Pauses Enrollment in First Phase 3 Trial of Squalamine| OHR PHARMACEUTICAL (NASDAQ: OHRP) | Delayed: 5.39 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.39 | 52 Week High | $6.56 | |||
| Open | $1.75 | 52 Week Low | $2.44 | |||
| Day High | $5.39 | P/E | N/A | |||
| Day Low | $5.39 | EPS | $-0.28 | |||
| Volume | 0 | |||||
